QuestionSBA
QuestionChoice
Monoamine oxidase inhibitors (MAO-Is) are part of the treatment of Parkinson's disease. They reduce the breakdown of monoamine neurotransmitters (such as dopamine).
10000777
b
Monoamine oxidase inhibitors
QuestionChoice
This is a recent non-drug treatment for Parkinson's disease. There are different targets in the brain depending on the symptoms experienced.
10000779
d
Deep brain stimulation
QuestionChoice
Anticholinergics were the first-line drug treatment for Parkinson's disease in the past. They help treat tremor, but have many side effects, such as cognitive decline.
10000778
c
Anticholinergics
QuestionChoice
Entacapone is an additional treatment with levodopa. It reduces the peripheral metabolism of L-dopa, increasing efficacy. However, it worsens side effects.
10000780
e
Entacapone
QuestionChoice
Parkison's disease involves the destruction of dopaminergic neurons in the substantia nigra, reducing dopamine transmission in the brain. Levodopa aims to replace dopamine and is the gold-standard treatment in Parkinson's disease.
10000776
a
Levodopa
Concept
Chapter
2693
3747
Parkinson's Disease
Topic
141
Neurology
12702
What drug is the first-line treatment of Parkinson's disease?
a